{"id":9392,"date":"2025-08-14T09:42:09","date_gmt":"2025-08-14T14:42:09","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9392"},"modified":"2025-08-14T09:45:07","modified_gmt":"2025-08-14T14:45:07","slug":"nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306b\u304a\u3051\u308bMCO-010\u907a\u4f1d\u5b50\u975e\u7279\u7570\u7684\u6cbb\u7642\u85ac\u3092\u8a55\u4fa1\u3059\u308bSTARLIGHT\u7b2c2\u76f8\u8a66\u9a13\u306e\u8ad6\u6587\u767a\u8868\u3092\u767a\u8868"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"9392\" class=\"elementor elementor-9392\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 style=\"text-align: center;\"><i>\u306e<\/i><i>\u00a0STARLIGHT\u8a66\u9a13\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306e\u8996\u529b\u6539\u5584\u3092\u5b9f\u8a3c\u3057\u305f\u6700\u521d\u3067\u552f\u4e00\u306e\u81e8\u5e8a\u8a66\u9a13\u3067\u3059\u3002.<\/i><\/h3><h3 style=\"text-align: center;\"><i>MCO-010\u00a0<\/i><i>48\u9031\u9593\u3067\u5e73\u5747\u8996\u529b12 ETDRS\u6587\u5b57\u306e\u6539\u5584\u3092\u793a\u3057\u305f\u00a0<\/i><i>\u9ec4\u6591\u90e8\u306b\u9650\u5c40\u3057\u305f\u840e\u7e2e\u306e\u3042\u308b\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306e\u5831\u544a\u306f\u306a\u304b\u3063\u305f\u3002.<\/i><\/h3><h3 style=\"text-align: center;\"><i>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u00a0<\/i><i>FDA\u3068\u306e\u7b2c2\u76f8\u7d42\u4e86\u4f1a\u8b70\u3092\u5b8c\u4e86\u3057\u3001\u00a0<\/i><i>2025\u5e74\u672b\u307e\u3067\u306b\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u767b\u9332\u7533\u8acb\u306b\u5411\u3051\u305f\u7b2c3\u76f8\u81e8\u5e8a\u8a66\u9a13\u3092\u958b\u59cb\u3059\u308b\u4e88\u5b9a\u3002<\/i><i>.<\/i><\/h3><p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2025\u5e748\u670814\u65e5<\/span><\/span> \u2014\u00a0<b><a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e,<\/a><\/b>\u00a0\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308b\u8996\u529b\u55aa\u5931\u306b\u82e6\u3057\u3080\u60a3\u8005\u306e\u305f\u3081\u306e\u65b0\u898f\u907a\u4f1d\u5b50\u975e\u4f9d\u5b58\u578b\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3068\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u306f\u672c\u65e5\u3001STARLIGHT\u81e8\u5e8a\u8a66\u9a13\u306e\u826f\u597d\u306a\u7d50\u679c\u304c\u767a\u8868\u3055\u308c\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u305f\u3002\u00a0<i><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025003621\" target=\"_blank\" rel=\"nofollow noopener\">eClinical Medicine\uff08\u30e9\u30f3\u30bb\u30c3\u30c8\u30fb\u30c7\u30a3\u30b9\u30ab\u30d0\u30ea\u30fc\u30fb\u30b5\u30a4\u30a8\u30f3\u30b9\u306e\u4e00\u90e8\uff09<\/a><\/i><i>.<\/i>\u00a0STARLIGHT\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u60a3\u8005\u306e\u8996\u529b\u6539\u5584\u3092\u5b9f\u8a3c\u3057\u305f\u6700\u521d\u3067\u552f\u4e00\u306e\u81e8\u5e8a\u8a66\u9a13\u3067\u3059\u3002.<\/p><p>STARLIGHT\u306f\u3001SD\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u4f4e\u4e0b\u3092\u6709\u3059\u308b6\u540d\u306e\u88ab\u9a13\u8005\u3092\u5bfe\u8c61\u306b\u3001\u907a\u4f1d\u5b50\u975e\u4f9d\u5b58\u7684\u306aMCO-010\u7642\u6cd5\u306e\u785d\u5b50\u4f53\u5185\u5358\u56de\u6ce8\u5c04\u306e\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u8a2d\u8a08\u3055\u308c\u305f\u3001\u7b2c2\u76f8\u975e\u76f2\u691c\u8a66\u9a13\u3067\u3059\u3002.<\/p><p>\u4e3b\u306a\u8abf\u67fb\u7d50\u679c\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/p><ul type=\"disc\"><li>\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u308948\u9031\u76ee\u307e\u3067\u306e\u6700\u826f\u77ef\u6b63\u8996\u529b\uff08BCVA\uff09\u306e\u5e73\u5747\u6539\u5584\u5ea6\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3057\u305f\u3002<ul type=\"disc\"><li>\u3059\u3079\u3066\u306e\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u30a6\u30a7\u30a2\u30e9\u30d6\u30eb\u5f31\u8996\u88dc\u52a9\u5177\u306a\u3057\u306e\u5834\u5408\u3068\u30a6\u30a7\u30a2\u30e9\u30d6\u30eb\u5f31\u8996\u88dc\u52a9\u5177\u3042\u308a\u306e\u5834\u5408\u3067\u3001\u305d\u308c\u305e\u308cETDRS\u6587\u5b57\u6570+5.5\u3068+9.0\u3068\u306a\u3063\u305f\u3002.<\/li><li>\u9ec4\u6591\u90e8\u306b\u9650\u5c40\u3057\u305f\u840e\u7e2e\u306e\u3042\u308b\u4eba\u3067\u306f\u3001\u30a6\u30a7\u30a2\u30e9\u30d6\u30eb\u5f31\u8996\u88dc\u52a9\u5177\u306a\u3057\u306e\u5834\u5408\u3068\u3042\u308a\u306e\u5834\u5408\u3067\u3001\u305d\u308c\u305e\u308c+12.0\u304a\u3088\u3073+32.0 ETDRS\u6587\u5b57\u3002.<\/li><\/ul><\/li><li>\u4e00\u90e8\u306e\u60a3\u8005\u3067\u306f\u3001\u6cbb\u7642\u5f8c\u308f\u305a\u304b4\u9031\u9593\u3067\u8996\u529b\u6539\u5584\u304c\u898b\u3089\u308c\u3001\u305d\u306e\u52b9\u679c\u306f\u7814\u7a76\u671f\u9593\u3092\u901a\u3057\u3066\u7dad\u6301\u3055\u308c\u305f\u3002.<\/li><li>MCO-010\u306f\u5fcd\u5bb9\u6027\u304c\u826f\u597d\u3067\u300148\u9031\u9593\u306b\u308f\u305f\u308a\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u5831\u544a\u3055\u308c\u306a\u304b\u3063\u305f\u3002.<\/li><\/ul><p>\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08\u82e5\u5e74\u6027\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3068\u3082\u547c\u3070\u308c\u308b\uff09\u306f\u3001\u5c0f\u5150\u306e\u8996\u529b\u55aa\u5931\u306e\u4e3b\u8981\u306a\u539f\u56e0\u3067\u3042\u308a\u3001\u7c73\u56fd\u3067\u306f4\u4e07\u4eba\u4ee5\u4e0a\u304c\u7f79\u60a3\u3057\u30012\u4e07\u4eba\u4ee5\u4e0a\u304c\u6cd5\u7684\u5931\u660e\u72b6\u614b\u306b\u3042\u308b\u3002\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3067\u306f\u3001\u9ec4\u6591\u90e8\u306e\u5149\u53d7\u5bb9\u4f53\u304c\u5909\u6027\u3057\u3001\u4e2d\u5fc3\u8996\u529b\u306e\u55aa\u5931\u306b\u3064\u306a\u304c\u308b\u3002\u73fe\u5728\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308b\u627f\u8a8d\u3055\u308c\u305f\u6cbb\u7642\u6cd5\u306f\u306a\u3044\u3002.<\/p><p>\u201c\u300c\u3053\u308c\u306f\u975e\u76f2\u691c\u8a66\u9a13\u3067\u3057\u305f\u304c\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306e\u8996\u529b\u6539\u5584\u3092\u5b9f\u8a3c\u3057\u305f\u6700\u521d\u306e\u7814\u7a76\u306e\u4e00\u3064\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u60a3\u8005\u306f\u901a\u5e38\u3001\u751f\u6daf\u306b\u308f\u305f\u3063\u3066\u4e0d\u53ef\u9006\u7684\u306a\u4e2d\u5fc3\u8996\u529b\u55aa\u5931\u3092\u7d4c\u9a13\u3059\u308b\u305f\u3081\u3001\u3053\u308c\u306f\u6ce8\u76ee\u3059\u3079\u304d\u767a\u898b\u3067\u3059\u300d\u3068\u4ed8\u3051\u52a0\u3048\u305f\u3002\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4488615-1&h=1608611289&u=https%3A%2F%2Furl.avanan.click%2Fv2%2Fr01%2F___https%3A%2Furldefense.proofpoint.com%2FA7dzwq%3Fz%3Dmyyux-8F__rji.rnfrn.jiz_kfhzqyD_gDwts-7Iq-7Iqfr-7Iri%26i%3DIBRLfV%26h%3DjzL4xyhfYIqqAnrJSbgao2wBvTk-A%2FF_Hiuls0knnRR%26w%3DwlVPiylV5SfKWXYNqoZGHixACbVoRTARH8hXKnE6KSJ%26r%3Df004s34KPNHpKl1uQqhZnTz7q_8%2F8_Oxl5VGhQQ_IET15iRkYfunt1xUsZtQ6rLW%26x%3DJNN%2FZjtpIyfy7jr3k_pc6S7H44t1PhA1c1I2C%2FRS*%7E*Wl%26j%3D___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86NjM2NmU3MGYwOGZjMDcxNWVhNTY4YzM0NmQ4NTcyNDE6NzpkMWY1OjZmMTc1MDhiNDc3NmMwZmE2N2RhNmRhZTBjYzBlMjc0YzkzZjk2ODFiYzdiNjYxZDMyMWNlMWUxNzVjYzk0ZDQ6aDpUOlQ&a=Byron+Lam%2C+MD%2C+Professor+of+Ophthalmology+at+Bascom+Palmer+Eye+Institute\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"xn-person\">\u30d0\u30a4\u30ed\u30f3\u30fb\u30e9\u30e0<\/span>, \u533b\u5b66\u535a\u58eb\u3001\u30d0\u30b9\u30b3\u30e0\u30fb\u30d1\u30fc\u30de\u30fc\u773c\u79d1\u7814\u7a76\u6240\u773c\u79d1\u5b66\u6559\u6388<\/a>, STARLIGHT\u8a66\u9a13\u306e\u7b46\u982d\u8457\u8005\u517c\u4e3b\u4efb\u7814\u7a76\u8005\u3067\u3042\u308b\u3002\u300c\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306b\u5bfe\u3059\u308bMCO-010\u306e\u7b2c3\u76f8\u81e8\u5e8a\u8a66\u9a13\u306b\u53c2\u52a0\u3057\u3001\u3053\u306e\u6709\u671b\u306a\u6cbb\u7642\u6cd5\u306e\u627f\u8a8d\u306b\u5411\u3051\u305f\u9032\u5c55\u306b\u8ca2\u732e\u3067\u304d\u308b\u3053\u3068\u3092\u5927\u5909\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u300d\u201c<\/p><p>\u201c\u300c\u6cbb\u9a13\u306b\u53c2\u52a0\u3057\u3066\u304f\u3060\u3055\u3063\u305f\u60a3\u8005\u69d8\u3068\u7814\u7a76\u8005\u306e\u7686\u69d8\u306b\u611f\u8b1d\u3044\u305f\u3057\u307e\u3059\u300d\u3068\u4ed8\u3051\u52a0\u3048\u305f\u3002\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4488615-1&h=274283711&u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fnanostherapeutics.com%2Fwho-we-are%2Fsamarendra-mohanty%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86NWVlNTM3ZjAzZTU0YzUwZGZmOGUzMWQ4OGFlNjcwYzU6NjphOTFjOjM1MWFlNzhjMGM1ZGM2ZDFkMzAzZGU2YmM5ZDJlNmI0YTY2NWUwOTA4NDgzZjQ0NzZmODVmN2RkZDlhYjk2Nzg6cDpUOk4&a=Samarendra+Mohanty%2C+PhD%2C+President+%2F+Chief+Scientific+Officer\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"xn-person\">\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3<\/span>, \u535a\u58eb\u53f7\u53d6\u5f97\u3001\u793e\u9577\u517c\u6700\u9ad8\u79d1\u5b66\u8cac\u4efb\u8005<\/a>. \u300cSTARLIGHT\u8a66\u9a13\u3067SD\u60a3\u8005\u306b\u5bfe\u3057\u3066\u5f97\u3089\u308c\u305f\u7d50\u679c\u306f\u3001\u907a\u4f1d\u5b50\u975e\u4f9d\u5b58\u578b\u306eMCO-010\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u6cbb\u7642\u53ef\u80fd\u6027\u3092\u88cf\u4ed8\u3051\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u3068\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306e\u4e21\u65b9\u306e\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3051\u308b\u826f\u597d\u306a\u7d50\u679c\u3092\u3055\u3089\u306b\u767a\u5c55\u3055\u305b\u308b\u3082\u306e\u3067\u3059\u3002\u300d\u201c<\/p><p>\u51fa\u7248\u3055\u308c\u305f\u539f\u7a3f\u306e\u30bf\u30a4\u30c8\u30eb\u306f\u00a0<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025003621\" target=\"_blank\" rel=\"nofollow noopener\">\u201c<i>\u7c73\u56fd\u306b\u304a\u3051\u308b\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306e\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\uff08STARLIGHT\uff09\uff1a\u975e\u76f2\u691c\u591a\u65bd\u8a2d\u5171\u540c\u7b2c2\u76f8\u8a66\u9a13\u201d<\/i><\/a>, \u306f\u30aa\u30f3\u30e9\u30a4\u30f3\u3067\u5165\u624b\u53ef\u80fd\u3067\u3001\u8fd1\u65e5\u767a\u884c\u3055\u308c\u308b\u5370\u5237\u7248\u306b\u3082\u63b2\u8f09\u3055\u308c\u307e\u3059\u3002\u00a0<i>\u30e9\u30f3\u30bb\u30c3\u30c8\u8a8c\u3002.<\/i><\/p><p><b>MCO-010\u306b\u3064\u3044\u3066<\/b><b>\u00a0\u305d\u3057\u3066\u305d\u306e\u00a0<\/b><b>\u8fd1\u65e5\u516c\u958b\u00a0<\/b><b>STARGAZE\u7b2c3\u76f8\u8a66\u9a13<\/b><\/p><p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u72ec\u81ea\u306eMCO-010\uff08<i>\u30bd\u30f3\u30d4\u30ec\u30c1\u30b2\u30cd\u30fb\u30a4\u30b9\u30c6\u30d1\u30eb\u30dc\u30d9\u30af<\/i>MCO-010\u306f\u3001\u9032\u884c\u3057\u305f\u7db2\u819c\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u3092\u76ee\u7684\u3068\u3057\u305f\u30011\u56de\u9650\u308a\u306e\u9662\u5185\u785d\u5b50\u4f53\u5185\u6295\u4e0e\u306b\u3088\u308b\u907a\u4f1d\u5b50\u975e\u4f9d\u5b58\u578b\u6cbb\u7642\u6cd5\u3067\u3059\u3002MCO-010\u306f\u3001\u9ad8\u5bc6\u5ea6\u306e\u53cc\u6975\u7db2\u819c\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3057\u3066\u5149\u611f\u53d7\u6027\u306b\u3057\u3001\u5149\u53d7\u5bb9\u4f53\u7d30\u80de\u306e\u6b7b\u6ec5\u5f8c\u306b\u6b8b\u5b58\u3059\u308b\u8996\u899a\u56de\u8def\u3092\u5229\u7528\u3057\u307e\u3059\u3002MCO-010\u7642\u6cd5\u306f\u3001\u907a\u4f1d\u5b50\u691c\u67fb\u3001\u5916\u79d1\u7684\u4ecb\u5165\u3001\u307e\u305f\u306f\u7e70\u308a\u8fd4\u3057\u6295\u4e0e\u3092\u5fc5\u8981\u3068\u3057\u306a\u3044\u305f\u3081\u3001\u65e2\u5b58\u306e\u7db2\u819c\u8a3a\u7642\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u5185\u3067\u5e45\u5e83\u3044\u60a3\u8005\u306b\u9069\u7528\u53ef\u80fd\u3067\u3059\u3002.<\/p><p>STARGAZE\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306b\u304a\u3051\u308bMCO-010\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u8a2d\u8a08\u3055\u308c\u305f\u3001\u7b2c3\u76f8\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u8a66\u9a13\u3067\u3059\u3002\u7b2c2\u76f8\u8a66\u9a13\u7d42\u4e86\u4f1a\u8b70\u306e\u6210\u529f\u3092\u53d7\u3051\u3001FDA\u306e\u30ac\u30a4\u30c0\u30f3\u30b9\u306b\u6cbf\u3063\u3066\u3001\u3053\u306e\u627f\u8a8d\u7533\u8acb\u306b\u5411\u3051\u305f\u8a66\u9a13\u3067\u306f\u3001\u8907\u6570\u306e\u65bd\u8a2d\u3067\u7d0460\u540d\u306e\u60a3\u8005\u304c\u767b\u9332\u3055\u308c\u307e\u3059\u3002\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u306f\u3001\u6a19\u6e96\u8996\u529b\u8868\u3092\u7528\u3044\u305fBCVA\u306e\u5909\u5316\u3068\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u3068\u306e\u6bd4\u8f03\u3067\u3059\u3002\u91cd\u8981\u306a\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u3001\u591a\u8f1d\u5ea6\u5f62\u72b6\u8a8d\u8b58\u306e\u6539\u5584\u3092\u8a55\u4fa1\u3057\u307e\u3059\u3002\u4e3b\u8981\u306a\u7d50\u679c\u306f2027\u5e74\u306b\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002.<\/p><p>MCO-010\u304a\u3088\u3073Nanoscope Therapeutics\u306b\u95a2\u3059\u308b\u8a73\u7d30\u306b\u3064\u3044\u3066\u306f\u3001\u4ee5\u4e0b\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4488615-1&h=4272928033&u=https%3A%2F%2Fwww.nanostherapeutics.com%2F&a=www.nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanostherapeutics.com<\/a>.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<\/b><\/p><p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002RESTORE\u30d5\u30a7\u30fc\u30ba\u3067\u306e\u826f\u597d\u306a\u7d50\u679c\u3092\u53d7\u3051\u3066\u3001\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u5171\u540c\u3001\u7121\u4f5c\u70ba\u5316\u3001\u4e8c\u91cd\u76f2\u691c\u3001\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4488615-1&h=648193028&u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fclinicaltrials.gov%2Fstudy%2FNCT04945772___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6Njo0YWVjOmU5YTIyOGNiZDRhMzQ3NzJkNWE0NDg0MjliN2JlZjMxN2Q1ZmM4NWU2MTBiOWQwNjZkM2ZjZDZkMGQ5NjVjMWI6cDpUOk4&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3001FDA\u3078\u306eBLA\u7533\u8acb\u304c\u9806\u6b21\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\uff08<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4488615-1&h=1428603299&u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fclinicaltrials.gov%2Fstudy%2FNCT05417126___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6NjpjMWRkOmVmOTBkMjllMDdkZTAwZGRhNmY0NGIxZWVmYzExOWI2OWU5ZGY3YTRjYTQ5ZTMyZjZlOTQxYTJjOGZkMjM4YmM6cDpUOk4&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4488615-1&h=3026779660&u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fnanostherapeutics.com%2F2024%2F09%2F12%2Fnanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6NjoxM2E1OjdmZGE1NmRiYjg5MmIyYzAzOGRlYzc4YWY3ZmRlZmNmMjhlZjNkZmQ2Y2Y0MTE1ZWQ2MzMwMDg1MTAwMDAwYzk6cDpUOk4&a=Phase+3+registrational+trial\" target=\"_blank\" rel=\"nofollow noopener\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02025\u5e74\u306b\u767a\u58f2\u4e88\u5b9a\u306eMCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u810a\u9ac4\u6027\u7b4b\u840e\u7e2e\u75c7\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001IND\u7533\u8acb\u306b\u5411\u3051\u305f\u7814\u7a76\u6bb5\u968e\u306b\u3042\u308b\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u306e\u307b\u304b\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306b\u5bfe\u3059\u308bIND\u7533\u8acb\u6e96\u5099\u6bb5\u968e\u306e\u85ac\u5264\u304c\u542b\u307e\u308c\u3066\u3044\u307e\u3059\u3002.\u00a0<\/p><p><b>\u63a5\u89e6\uff1a<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The\u00a0STARLIGHT study is the first and only clinical trial to demonstrate vision improvement in patients with Stargardt disease. MCO-010\u00a0demonstrated mean visual acuity improvement of 12 ETDRS letters over 48 weeks in\u00a0patients with atrophy confined to the macula -with no reports of serious adverse events. Nanoscope\u00a0has completed an end of phase 2 meeting with the FDA and\u00a0plans to initiate a registration-enabling Phase 3 trial in Stargardt disease patients by the end of 2025. DALLAS,\u00a0Aug. 14, 2025 \u2014\u00a0Nanoscope Therapeutics Inc.,\u00a0a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of positive results from its STARLIGHT clinical trial in\u00a0eClinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-14T14:42:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-14T14:45:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease\",\"datePublished\":\"2025-08-14T14:42:09+00:00\",\"dateModified\":\"2025-08-14T14:45:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\"},\"wordCount\":800,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\",\"name\":\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-08-14T14:42:09+00:00\",\"dateModified\":\"2025-08-14T14:45:07+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306b\u304a\u3051\u308bMCO-010\u907a\u4f1d\u5b50\u975e\u7279\u7570\u7684\u7642\u6cd5\u3092\u8a55\u4fa1\u3059\u308bSTARLIGHT\u7b2c2\u76f8\u8a66\u9a13\u306e\u8ad6\u6587\u767a\u8868\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-08-14T14:42:09+00:00","article_modified_time":"2025-08-14T14:45:07+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease","datePublished":"2025-08-14T14:42:09+00:00","dateModified":"2025-08-14T14:45:07+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/"},"wordCount":800,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","url":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u306b\u304a\u3051\u308bMCO-010\u907a\u4f1d\u5b50\u975e\u7279\u7570\u7684\u7642\u6cd5\u3092\u8a55\u4fa1\u3059\u308bSTARLIGHT\u7b2c2\u76f8\u8a66\u9a13\u306e\u8ad6\u6587\u767a\u8868\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-08-14T14:42:09+00:00","dateModified":"2025-08-14T14:45:07+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=9392"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9392\/revisions"}],"predecessor-version":[{"id":9396,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9392\/revisions\/9396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=9392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=9392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=9392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}